Clinical Trial

Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence

Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The impact of fluciclovine (18F) PET on the management of participants with prostate cancer following negative or equivocal PSMA PET Imaging at the time of biochemical recurrence
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-04-29.
Trial Details
NCT Number NCT07569926
Lead Sponsor Blue Earth Diagnostics
Conditions Prostate Cancer
Enrollment 142 participants
Start Date 2026-06-01
Primary Completion 2027-12-31 (estimated)
Study Completion 2032-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-02